(firstQuint)Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial.

 This is a multicenter, randomized, double-blind, comparator-controlled study.

 The study consists of 2 parallel-dose treatment groups consisting of ulimorelin and metoclopramide.

 Approximately 120 mechanically ventilated, tube-fed patients with EFI will participate in this trial.

 To be eligible for study participation, the patients must be intolerant to continuous gastric tube feedings, with intolerance defined as having a gastric residual volume (GRV) of 500 mL on one or more measurements.

.

 Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial@highlight

The purpose of this study is to evaluate the effect Ulimorelin in patients with enteral feeding intolerance.

